Earnings call transcript: Immunocore Q2 2025 beats revenue forecast

Immunocore Holdings (IMCR) reported Q2 2025 revenue of $98 million, exceeding consensus by 6.48% and representing a 30% year-over-year increase, primarily driven by strong ChemTrak sales in US and European markets. Despite this revenue beat, EPS came in at -$0.20, missing expectations, which contributed to a modest 0.4% pre-market stock dip. However, the company significantly narrowed its net loss to $5 million from $36 million year-over-year and maintains a robust financial position with $883 million in cash, supporting ongoing substantial investments in its three Phase III oncology trials and expanding autoimmune pipeline.

Analysis

Immunocore Holdings (IMCR) reported a mixed but fundamentally strong second quarter for 2025, characterized by a significant revenue beat and a minor earnings shortfall. Total revenue reached $98 million, surpassing consensus forecasts of $92.04 million by 6.48% and marking a 30% year-over-year increase. This top-line performance was fueled by the robust commercial execution of its key product, ChemTrak, which saw impressive growth in both the US ($64 million, a 15% increase vs. Q2 2024) and Europe ($33 million, a 115% YoY increase). Despite the strong sales, earnings per share came in at -$0.20, missing the forecast of -$0.18, which reflects the company's escalating R&D expenditures tied to its ambitious clinical pipeline. Importantly, Immunocore demonstrated significant progress towards profitability by narrowing its net loss to $5 million from $36 million a year prior. The company maintains a formidable financial position, holding $883 million in cash and marketable securities and impressive gross margins of 92.32%, providing a strong foundation to fund its three ongoing Phase III trials and its strategic expansion into the autoimmune space.

Key Decisions for Investors

• Investors should view the EPS miss as a function of strategic investment in the pipeline, focusing instead on the long-term value drivers from the three Phase III oncology trials and the emerging autoimmune platform.
• Monitor ChemTrak's commercial momentum, particularly its strong 13-month real-world duration of therapy and market penetration, as its revenue stream is critical for funding R&D and de-risking the company's financial profile.
• Key near-term catalysts to watch are the completion of enrollment for the TEBIAM trial within the next 12 months and any updates on regulatory interactions, as pipeline progress is the primary catalyst for future share price appreciation.
• The strong balance sheet with $883 million in cash mitigates near-term financing risk, providing a substantial cushion to navigate the high-cost clinical development phase through key data readouts.